Peptide Receptor Radionuclide Therapy (PRRT) Market showing Compound annual growth rate and forecast

Peptide Receptor Radionuclide Therapy (PRRT) Market showing Compound annual growth rate and forecast till 2026

Peptide Receptor Radionuclide Therapy (PRRT) Market, by Disease Indication (Gastroenteropancreatic Neuroendocrine Tumor, Foregut Neuroendocrine Tumor, Midgut Neuroendocrine Tumor, and Hindgut Neuroendocrine Tumor) by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2019 – 2027

Peptide receptor radionuclide therapy (PRRT) is a type of molecular therapy, also known as radioisotope therapy that is used for treating neuroendocrine tumors. In this therapy a peptide similar to the natural hormone is combined with radioactive material such as Yttrium and Lutetium, to produce radionuclide which is then injected into the patient’s body. This combination binds to the neuroendocrine tumors in the body. It is a cell targeting type of therapy since it delivers a high dose of radiation directly to the tumor cells. Click To Read More On Peptide Receptor Radionuclide Therapy (PRRT) Market.

Global Peptide Receptor Radionuclide Therapy (PRRT) Market Drivers Increasing number of drug approvals by regulatory bodies is expected to drive the global peptide receptor radionuclide therapy market growth over the forecast period. For instance, in January 2018,

Advanced Accelerator Applications S.A. received an approval from U.S. Food & Drug Administration for Lutathera, a peptide receptor radionuclide therapy. It is used for treating gastroenteropancreatic neuroendocrine tumors. Its phase 3 study showed 79% reduction in the disease progression. Moreover, it is the only approved peptide receptor radionuclide therapy drug.

Furthermore, key players are also focused on research and development activities related to peptide receptor radionuclide therapy which is expected to accelerate the global peptide receptor radionuclide therapy market growth. For instance, in July 2017, National Institute of Health commenced its clinical trial study on Y-DOTATOC. The drug is currently in the early phase of trials, and is being evaluated for micro-dosing. It will be used for treating neuroendocrine tumors. Such development of drugs is expected to boost the global peptide receptor radionuclide therapy market growth.

Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/2731 Also, strategies such as mergers, acquisitions, partnerships, and collaborations by key players related to peptide receptor radionuclide therapy are expected to propel the global peptide receptor radionuclide therapy market growth over the forecast period. For instance, in January 2018, Novartis AG, a biopharmaceutical company acquired Advanced Accelerator Applications S.A., a manufacturer of nuclear medicine products, in order to expand Novartis AG’s product portfolio. This acquisition was for the diversification of oncology neuroendocrine tumor treatment and addition of the radiopharmaceutical technology platform to its portfolio. The growing number of acquisitions are expected to fuel demand for the global peptide receptor radionuclide therapy market.

Global Peptide Receptor Radionuclide Therapy (PRRT) Market Regional Analysis North America is expected to be a dominant region in the peptide receptor radionuclide therapy market.

Higher incidences of prostate cancer is expected to support the global peptide receptor radionuclide therapy market growth. According to Center of Disease Control and Prevention’s data for 2016, around 192,443 people suffered from prostate cancer and almost 30,370 died due to it. Prostate cancer is considered the fourth leading cause of death due to cancer. Hence, increasing prevalence of prostate cancer is expected to augment the peptide receptor radionuclide therapy market growth during the forecast period.

Global Peptide Receptor Radionuclide Therapy (PRRT) Market Taxonomy The global peptide receptor radionuclide therapy (PRRT) market is segmented on the basis of disease indications, distribution channels, and regions.

By Disease Indication •Gastroenteropancreatic Neuroendocrine Tumor •Foregut Neuroendocrine Tumor •Midgut Neuroendocrine Tumor •Hindgut Neuroendocrine Tumor

By Distribution Channel •Hospital Pharmacies •Retail Pharmacies •Online Pharmacies Global Peptide Receptor Radionuclide Therapy (PRRT) Market Key Players Some of the major player operating in the global peptide receptor radionuclide therapy (PRRT) market include, Novartis AG, ITM Solucin GmbH, National Institutes of Health, Australasian Gastro-Intestinal Trials Group, Toulouse University Hospital, Peking University, and others.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us: Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1–206–701–6702 Email: sales@coherentmarketinsights.com